Top Searched Resources

Bictegravir – A new Integrase Inhibitor in the pipeline

Bictegravir matches dolutegravir for first-line treatment in Phase 2 studies Paul Sax at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com Bictegravir, an investigational new integrase inhibitor, was highly potent, well tolerated and worked as well as dolutegravir (Tivicay – an existing …

Doravirine – a new NNRTI (Non-Nuke) option on the horizon

Kathleen Squires at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that reduced HIV viral load as well as boosted darunavir (a Protease Inhibitor) in a phase 3 clinical trial of people starting …

What is safe sex now? Does it include undetectable viral load and PrEP?

Treatment as prevention and pre-exposure prophylaxis (PrEP) provide new ways to safely avoid HIV, but this poses challenges to the ways in which communities understand and practice ‘safe sex’, Martin Holt of the University of New South Wales told a public …

What is the National Disability Insurance Scheme (NDIS)? How does it apply to PLHIV?

The National Disability Insurance Scheme (NDIS) is a new commonwealth support program for people under 65yo with a permanent disability impairment that affects activities of functional daily living. The program is now being progressively rolled out across Australian states and territories, …

Oral Health (Dental Access) Fact Sheet

[calameo code=002946133366c6f056387 width=420 height=272 autoflip=3 view=magazine mode=mini clickto=embed clicktarget=_blank clicktourl=undefined showsharemenu=false]

Aged Care Reforms – Increasing choice in home care

As the HIV-positive population ages through the life-extending benefits of HIV treatments, age-related illness will (and already have) become an increasing concern, such as heart disease, diabetes, kidney disease, bone density loss, and some cancers. Alongside of this medication and treatment …